Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.79 |
| ▸ | CDC7 | O00311 | 8/20 | 0.67 |
| ▸ | CDK1 | P06493 | 4/20 | 0.67 |
| ▸ | CDK2 | P24941 | 4/20 | 0.67 |
| ▸ | GSK3B | P49841 | 4/20 | 0.67 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.67 |
| ▸ | PLK4 | O00444 | 3/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.67 |
| ▸ | PRKCG | P05129 | 3/20 | 0.67 |
| ▸ | PRKACA | P17612 | 3/20 | 0.67 |
| ▸ | MARK3 | P27448 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | FRK | P42685 | 3/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194640 | 0.92 | JAK2 (0.76) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13732635 | 0.88 | JAK2 (1.00) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13730872 | 0.88 | JAK2 (0.65) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL4177356 | 0.87 | JAK2 (0.72) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13730639 | 0.87 | JAK2 (1.00) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13732436 | 0.86 | JAK2 (1.00) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL4184862 | 0.86 | JAK2 (0.73) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13730147 | 0.85 | JAK2 (0.82) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL4187207 | 0.85 | JAK2 (0.80) | JAK2CDC7CDK1CDK2GSK3B | |
| SCHEMBL13730541 | 0.84 | JAK2 (0.76) | JAK2CDC7CDK1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283224-B2 | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-15 | — | — | US | claimed |
| US-20140155421-A1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-06-05 | — | — | US | claimed |
| CN-103502241-A | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-01-08 | — | — | CN | claimed |
| EP-2699564-B1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-12-14 | — | — | EP | disclosed |
| US-9283224-B2 | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-15 | — | — | US | disclosed |
| US-20140155421-A1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-06-05 | — | — | US | disclosed |
| EP-2699564-A1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-02-26 | — | — | EP | disclosed |
| CN-103502241-A | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-01-08 | — | — | CN | disclosed |
| WO-2012143248-A1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155421-A1 | SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS | JAK1, MAP3K1, MAP3K20 | JAK2 11/4885CDC7 371/4885CDK1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.